Pharma: At its high - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma: At its high

Jul 1, 2003

June has been a very good month for the domestic pharma sector. After having made a poor start in 2003 due to stagnating domestic demand and the VAT fiasco, the sector is back in the limelight among investors. Infact, many of the pharma stocks are currently trading at their 52-week highs. But are these gains fundamentally driven or is it just another bubble about to be burst?

Gains made in the past one month
CompanyPrice on% Change 52-Week H/L
May 27 '03 (Rs) Jun 30 '03 (Rs)
Kopran Ltd254787.0%63 / 18
Lupin Ltd 17630070.7%306 / 90
Cadila Healthcare 11917648.5%148 / 110
Dr Reddy’s Laboratories 816109534.2%1,076 / 675
Aurobindo Pharma 28937128.5%363 / 191
Nicholas Piramal 27935025.3%334 / 205
Sun Pharma 28935021.1%362 / 258
Ranbaxy 65678519.7%765 / 485
Glenmark Pharma 25229717.9%293 / 186
Cipla 64875316.3%985 / 561
Wockhardt 3563642.3%500 / 306
BSE-SENSEX 3,082 3,607 17.0%3,590 / 2,828
* companies in bold are trading at their 52-week high.

Domestic pharma companies were recording poor growth rates in January-March 2003. Infact, the sector registered negative growth in February 2003. This was mainly on account of stagnancy in the anti-biotic segment. Moreover, in March 2003, confusion in relation to the implementation of VAT further affected the performance of these companies. However, with the government putting VAT on the back burner, the pharma sector has seen a revival of sorts since May. Growth is back in double-digits.

Even on the exports front, the US government brought cheer to the Indian pharma companies. The reduction in the approval time for generics will ease their entry into the US markets. This will benefit generic companies like Ranbaxy and Dr Reddy’s, which have many pending ANDA approvals. Ranbaxy received US-FDA approval for ‘Isotretinoin’ capsules, anti-HIV drug ‘Ganciclovir’ and also a tentative approval for ‘Ofloxacin’. This would provide a fillip to Ranbaxy. This is filtered into the stock trading at its new 52-week high levels.

Further, with the US government now widening the scope of prescription drugs under its health insurance scheme by including generics, demand for these is expected to get a further boost. Apart from Ranbaxy and Dr Reddy’s, companies like Lupin Laboratories and Glenmark are also planning to foray into the US generics market. In June, Lupin Laboratories filed 2 ANDAs raising its total ANDA tally to 5, while Glenmark entered into a marketing agreement with Lannett Company Inc for marketing the ANDAs that the company would file. As can be seen from the table above, Lupin is among the top gainers in the last one month.

The Indian government’s announcement that the healthcare industry is likely to get many fiscal incentives further improved sentiments. On the operations front, Nicholas Piramal and Ranbaxy have restructured their high cost debts with low cost ones, while Lupin has repaid debt including preference shares worth Rs 480 m. Sun Pharma has benefited from its reduction in inventory. These measures will reduce the pressure on bottomline and improve profitability of these companies.

Apart from the above general grounds, the clearing of the amalgamation of Cadila Healthcare with German Remedies by the High Court was the key trigger for the rise in the prices of this stock. Cadila is also at its new 52-week high levels.

Thus, there are adequate reasons to justify the sharp rise in the stock prices of domestic pharma companies. However, an across the sector rise in the prices is not justified. The impact of the above events on individual companies is the determining factor that will differentiate fundamentally driven companies from speculation driven ones. Thus, though the pharma sector has bright prospects going forward, investors will have to exercise caution while choosing companies from within the sector.

Equitymaster requests your view! Post a comment on "Pharma: At its high". Click here!

  

More Views on News

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

Krsnaa Diagnostics IPO Opens Tomorrow: Key Points to Consider (Views On News)

Aug 3, 2021

Krsnaa Diagnostics grey market premium is at around Rs 440 from its issue price of Rs 933-954.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Dec 6, 2021 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS